the results of cytogenetic assessment performed in 190
Results patients drawn from the first 1400 cases entered into AML Cytogenetic assessment at bone marrow harvest 10. It therefore affords the opportunity to evaluate the suitability of cytogenetic examination at a defined point in therOf the 1400 patients considered in this study, 190 with apy for residual disease detection, and to determine the documented diagnostic karyotype had a successful cytoprognostic significance of such results in the context of subgenetic assessment performed at the time of bone marrow sequent transplantation procedures.
harvest. In 171/190 (90%) this examination was normal; these patients were subsequently grouped according to their cytogenetic findings at diagnosis, as presented in Table 1 .
Considering the 19 patients in whom abnormal metaphases were detected at the time of bone marrow harvest, Patients and methods in eight patients the same abnormality was reported as had been found at diagnosis, while 11 patients had cytogenetic abnormalities detectable at harvest which were not present This study considers cytogenetic data collated from the first at diagnosis, see Tables 2 and 3 . 1400 patients entered into AML 10, providing a minimum follow-up period of 2 years from the time of diagnosis. The
Outcome of patients with abnormal cytogenetics at bone trial, which included children and adults up to the age of marrow harvest 55 years, commenced in 1988 and closed in 1995, having amassed 1966 patients. These were predominantly recruited Eight patients had the same karyotypic abnormality at bone from the UK, but some cases were included from Ireland marrow harvest as at diagnosis, indicative of persistence of and New Zealand. Patients were randomised to receive the disease-related clone despite morphological CR. AML induction therapy with two courses of DAT or ADE. The in three such patients was associated with cytogenetic third and fourth courses of consolidation chemotherapy abnormalities considered to confer a poor prognosis comprised MACE and MIDAC respectively, with bone (patients 2, 5 and 6, Table 2 ); all demonstrated monosomy marrow harvest being undertaken between the third and 7 and in patient 6 this formed part of a complex karyotype together with monosomy 5. Therefore, karyotypes associafourth treatment courses for those lacking sibling donors, ted with poor risk were over-represented amongst this provided morphological complete remission (CR) at this group, contrasting with the cytogenetic findings at diagstage was confirmed (Ͻ5% blasts on bone marrow nosis in patients with normal cytogenetics at harvest examination).
11 This study considers the results of 190 suc- (Table 1) , where the relative frequencies of karyotypes cessful cytogenetic analyses of bone marrow taken at the associated with favourable, intermediate and adverse protime of or immediately before bone marrow harvest.
gnoses were more representative of newly diagnosed AML Reasons for failure to perform cytogenetic assessment at (as determined in the whole patient population). this stage included death during prior induction or consoliTwo patients with evidence of contamination of hardation courses, failure to achieve morphological remission, vested marrow by the disease-related clone were autodecision to undertake allogeneic transplantation with no grafted in first morphological CR (patients 1 and 2); both back-up harvest being performed or failure to forward an patients lacked an HLA-matched donor. Patient 1, a 25-aliquot of harvested marrow for cytogenetic assessment.
year-old male, presented with AML associated with +8, The outcome of patients in whom cytogenetics was not perinv(16); a karyotype considered to confer a relatively formed at harvest did not differ significantly from the group favourable prognosis. 9,10 Marrow harvested after three in whom this examination was undertaken (DFS at 5 years:
courses of chemotherapy revealed one cell with the +8, harvest cytogenetics done, 47%; cf not done, 46%, 2P = 0.78). Cytogenetic analyses were performed at local laboratories or where no such service was available, exam- inv(16) diagnostic abnormality amongst 19 normal cells. of sepsis following the final chemotherapy consolidation course. However, four patients (patients 5-8), two of whom This patient had achieved morphological CR following the second course of chemotherapy. Due to renal impairment had poor-risk cytogenetic abnormalities, relapsed within 6.0-6.5 months of bone marrow harvest. complicating the first consolidation course, an elective autograft was performed using cyclophosphamide/TBI conIn 11 patients cytogenetic abnormalities were found at harvest which were not present at diagnosis, the details of ditioning. Despite contamination of the harvest with the leukaemic clone the patient remains in remission 5.5 years which are presented in Table 3 . The majority of this group of patients had a normal karyotype at diagnosis (seven post-ABMT, and bone marrow cytogenetics performed 1 month and 6 months post-ABMT revealed only normal patients) and non-clonal abnormalities at harvest (eight patients). Of the three patients with acquired clonal abnormetaphases. Patient 2, a 26-year-old male, presented with AML associated with inv(3q),−7; a karyotype considered malities (patients 14, 18, 19, Table 3 ), all remain in first CR 2.5-4.5 years after bone marrow harvest with no transto confer a poor prognosis. Since he had only achieved CR after three courses of chemotherapy an elective ABMT plantation procedure having been performed. The acquisition of clonal or non-clonal changes, following induction using busulfan/cyclophosphamide conditioning was performed using marrow harvested following the fourth course and consolidation chemotherapy, which were not present at diagnosis showed no evidence of being prognostically of treatment. Relapse occurred 5 months following ABMT, with cytogenetics confirming persistence of the original significant, see Figure 1 . In contrast, persistence of the disease-related clone detectable by conventional cytogenetics clone.
Six patients with cytogenetic evidence of persistence of at the time of bone marrow harvest predicted a poor prognosis compared to patients with normal karyotype at the the disease-related clone, at the time of bone marrow harvest, were not transplanted in first morphological CR same stage. Differences in survival outcome could not be accounted for by the nature of post-consolidation therapy: (patients 3-8, Table 2 ). The significance of this phenomenon in two patients with intermediate-risk abnormalities of the group with abnormal karyotype at diagnosis and normal cytogenetics at harvest, 41 patients proceeded to bone (patients 3 and 4), could not be determined, as both died Table 3 Outcome of 11 patients with cytogenetic abnormalities present at bone marrow harvest that were not detected at the time of diagnosis 46,XX,t(6;5) [2] marrow transplantation in first CR (15 allogeneic, 26 ABMT); while amongst those with normal karyotype assessment at both diagnosis and harvest, 28 received transplants (five allogeneic, 23 ABMT).
Discussion
Cytogenetic assessment has been found to provide one of the most valuable indicators of prognosis in AML, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] although there have been relatively few studies addressing the suitability of this technique to residual disease detection. [14] [15] [16] This reflects two limitations of cytogenetic analy- sis; first as demonstrated in this study a significant number ing and particularly PCR-based methods. 17 However, the -. -. -., persistence of same cytogenetic abnormality at diagnosis and harvest, n = 8.
latter techniques have their own limitations and the improved sensitivity associated with PCR has as yet failed chemotherapy/radiotherapy and in favour of this model, two patients acquired chromosome 7 defects (del(7q), −7) to yield universally applicable prognostic information which can be incorporated into patient management. For associated with myelodysplastic changes. However, the authors also suggested that in some cases acquisition of example a number of studies have reported detection of AML1-ETO transcripts in t(8;21) AML in long-term unrelated karyotypic abnormalities could merely be a reflection of the relative insensitivity of conventional cytoremission with no adverse effect on prognosis, 18,19 whereas in acute promyelocytic leukaemia current widely applied genetic techniques, failing to detect a minor clone present at diagnosis which subsequently became apparent in PCR protocols are insufficiently sensitive to identify residual disease in all patients who ultimately relapse 20, 21 remission due to a relative growth advantage in the presence of chemotherapy. Acquisition of previously unidentiand PCR positivity in remission is more a marker for early relapse rather than for minimal residual disease. 21 It is clear fied clonal or non-clonal abnormalities has also been detected in up to 32% AML cases post-ABMT employing that the prognostic significance and source of PCR positivity must be established in each subtype of AML.
cyclophosphamide/TBI conditioning and mafosfamide purged marrow. 23 In this setting re-emergence of the origThere has only been one large previous study evaluating cytogenetics as a means of detecting residual disease in inal leukaemic clone heralded clinical relapse, whereas detection of cytogenetic changes that had not been ident-AML. 16 Freireich et al assessed bone marrow cytogenetics in clinical remission in 71 patients who were selected on ified at any previous stage of treatment was not predictive of a poor outcome. 23 Similarly, in the present study clonal the basis of good or poor risk cytogenetic features at diagnosis, drawn from a total group of 725 patients with AML or non-clonal changes detected at the time of bone marrow harvest that were unrelated to the karyotype at diagnosis accrued between 1975 and 1987. The presence of persistent cytogenetic abnormalities in remission in 20 patients (28%)
were found to lack prognostic significance (see Figure 1 ), although it should be noted that one patient with del(7q) was found to be highly predictive of relapse; however, the study also highlighted the insensitivity of such an approach identified at harvest subsequently developed secondary MDS and that the number of patients is small. to detect residual disease, since 25/51 patients with a normal karyotype also relapsed.
Eight of 101 (8%) patients with an abnormal karyotype at presentation demonstrated persistence of the clonal The present study considers a large unselected group of patients, drawn from a national trial in which patients, apart abnormality at bone marrow harvest, confirming that cytogenetics can detect evidence of residual leukaemia in the from the randomisation to transplantation in first CR, received equivalent induction and consolidation therapy. In presence of normal marrow morphology. Three of eight patients in this group had cytogenetic abnormalities assocontrast to other studies, cytogenetic assessment was performed at a defined time-point in the treatment protocol, ie ciated with poor prognosis, as compared to 10 of 89 (11%) patients with clonal abnormalities detected at diagnosis at bone marrow harvest, enabling results to be considered in the context of subsequent transplantation procedures. Bone who ultimately had normal cytogenetics at harvest. Two patients with cytogenetic evidence of residual disease in marrow cytogenetics were evaluated in 190 patients in remission from AML at the time of bone marrow harvest.
harvested marrow received ABMT in first CR: one patient with adverse cytogenetics relapsed within 5 months of In 171 (90%) patients, the examination was normal. Consideration of the cytogenetic findings in this group at prestransplantation; whereas, the other with favourable cytogenetics at presentation (+8, inv16) remains in CR 5.5 years entation suggested that they were broadly representative of de novo patients entered into AML 10, although patients post-ABMT. Of six patients with cytogenetically defined persistent disease in harvested marrow that were not transwith adverse cytogenetics were under-represented consistent with their poor remission rate and tendency to relapse planted in first CR, four relapsed within 6.5 months from the time of harvest (two adverse cytogenetic group; two rapidly. Nineteen (10%) patients demonstrated abnormal cytogenetics at harvest. For the purposes of this study, sinintermediate risk) and two died of sepsis (both intermediate-risk) during the final consolidation course. Therefore, gle-cell and non-clonal abnormalities that were not detected at the time of diagnosis were also reported to determine persistence of cytogenetically detectable disease was found to predict a poor prognosis, see Figure 1 . The relatively low whether they were of any significance to long-term prognosis or the efficacy of ABMT. Acquisition of such changes frequency of persistent chromosomal abnormalities in the present study compared with that of Freireich et al 16 may was apparent in eight patients and in most cases presumably reflected a non-specific chemotherapy-related effect or reflect a number of factors: in the latter study a greater proportion of patients with poor risk karyotypes were possibly was caused by fluorodeoxyuridine used in the preparation of cytogenetic spreads, and indeed repeat karyincluded, time-points at which karyotypic analyses were undertaken were very variable and in some cases cytootype analysis performed in one such patient on subsequent relapse revealed different abnormalities from those detected genetic results may have purely reflected detection of early relapse rather than residual disease. Furthermore, some at harvest. In three patients cytogenetic assessment at bone marrow harvest revealed clonal changes which had not patients included were treated up to 20 years ago suggesting that at least some would have received less aggressive probeen identified at any prior stage of therapy. This confirms a recent report by Kudoh et al, 22 concerning the emergence tocols than that employed in the AML 10 trial. Contamination of autologous marrow with residual leuof clonal cytogenetic abnormalities, unrelated to the karyotype at presentation, in four patients whilst in morphologikaemia in addition to reduced graft-versus-leukaemia effect have been considered to account for the increased relapse cal remission from AML. Kudoh and colleagues postulated that this phenomenon could be secondary to previous rate associated with ABMT in comparison to allogeneic
